In a meta-analysis of nearly 70,000 individuals, researchers estimated that low-frequency coding variants contribute about 5 percent of multiple sclerosis risk.
A team led by the University of British Columbia homed in on a variant that linked to increased liver enzyme levels and liver injury during interferon-β treatment.
A large meta-analysis and functional genomic assessment of a risky HLA haplotype uncovered hypomethylation that alters immune-related expression at the locus.
The partners will integrate genomic, imaging, and other data to identify new therapies and personalize treatments for patients with neurological and neurodegenerative diseases.
A pair of studies has established a potential role for specific gut bacteria in the progression of MS, suggesting therapeutic targeting of the microbiota as a potential treatment.
